

Prepared on: 24/10/2025

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of this investment product and complements the Prospectus¹.
- It is important to read the Prospectus before deciding whether to purchase the product. If you do not have a copy, please contact us to ask for one.
- You should not invest in the product if you do not understand it or are not comfortable with the accompanying risks.
- If you wish to purchase the product, you will need to make an application in the manner set out in the Prospectus.

Franklin Templeton Investment Funds
– Franklin Genomic Advancements Fund (the “Fund”)

Product Type	Investment Company	Launch Date	15/10/2021
Investment Manager	Franklin Advisers, Inc.	Depository	J.P. Morgan SE – Luxembourg Branch
Management Company	Franklin Templeton International Services S.à r.l.	Dealing Frequency	Daily (Dealing Days only)
Trustee	Nil	Expense Ratio for Financial Year ended 30/06/2024	<u>Share Class</u>
Capital Guaranteed	No		<u>Range</u>
			A 1.80%

PRODUCT SUITABILITY

WHO IS THE PRODUCT SUITABLE FOR? The Fund is <u>only</u> suitable for investors who are looking to: • invest in a Fund compliant with Article 8 of the SFDR • achieve capital appreciation by investing in equity securities of companies operating within health care related industries; and • invest for the medium to long term. The principal may be at risk.	Further Information Refer to “Fund Information, Objectives and Investment Policies” of the Luxembourg Prospectus.
--	---

KEY PRODUCT FEATURES

WHAT ARE YOU INVESTING IN? • You are investing in an open-ended collective investment scheme constituted in Luxembourg as a UCITS that aims to provide you with capital appreciation. • Under normal circumstances, you will receive regular distributions out of income depending on the distribution share classes you are investing in. Any distributions out of the capital of the Fund will reduce the NAV of the Fund.	Refer to “Investment Objective, Focus and Approach of the Funds” section of the Singapore prospectus, and the “Dividend Policy” section of the Luxembourg Prospectus.
--	---

Investment Strategy

• The Fund's investment objective is capital appreciation. • The Fund invests principally in equity securities of companies that are relevant to the Fund's investment theme of genomic advancements. Equity securities generally entitle the holder to participate in a company's general operating results. While the Fund invests predominantly in common stocks, it could also invest in preferred stock, convertible securities and warrants on securities. • Companies relevant to the Fund's investment theme of genomic advancements are those that the Investment Manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by	Refer to “Investment Objective, Focus and Approach of the Funds” section of the Singapore Prospectus.
---	---

offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes. The Investment Manager also considers Environmental, Social and Governance (ESG) factors as an integral component of its fundamental investment research and decision process. The Environmental and/or Social characteristics (within the meaning of Article 8 SFDR) promoted by the Fund are detailed in the Appendix G of the Luxembourg Prospectus.	
Parties Involved	
WHO ARE YOU INVESTING WITH? - The investment company is Franklin Templeton Investment Funds. - The investment manager is Franklin Advisers, Inc. - The management company is Franklin Templeton International Services S.à r.l. - The depositary is J.P. Morgan SE – Luxembourg Branch. - The Singapore representative is Templeton Asset Management Ltd.	Refer to “Management and Administration” section of the Singapore Prospectus for more information on the role and responsibilities of these entities and what happens if they become insolvent.
KEY RISKS	
WHAT ARE THE KEY RISKS OF THIS INVESTMENT? The value of the product and its dividends or coupons may rise or fall. These risk factors may cause you to lose some or all of your investment.	Refer to the “Risk Factors” section of the Singapore Prospectus and “Risk Considerations” section of the Luxembourg Prospectus.
Market and Credit Risks	
Your investments are exposed to equity markets risk – Your investments may be subject to significant price movements due to the impact of economic, political, market, and issuer-specific factors.	
Liquidity Risks	
Your investments are exposed to liquidity risks of the underlying investments – Under exceptional market conditions the manager may be forced to sell assets of the fund at a discount in order to meet continued redemption requests. The Fund is not listed, and you can realize your Shares only on Dealing Days – There is no secondary market for the Fund. All redemption requests should be submitted in the manner set out in the Prospectus. Your realization request may be deferred or suspended – Redemptions of Shares may be deferred when more than 10% of the value of the Fund’s Shares are redeemed or exchanged on any one Dealing Day. Your right to realize Shares may also be temporarily suspended under certain circumstances as described in the Prospectus.	Refer to the sections “Sale of Shares” and “Suspension of Valuation, Issue, Sale and Switching of Shares” of the Singapore Prospectus.
Product-Specific Risks	
Your investments are exposed to concentration risk – The Fund invests primarily in a single sector, market or region, and as a result is subject to higher concentration risk and potentially greater volatility compared to funds following a more diversified policy. Your investments are exposed to thematic investing risk – Companies within a Fund’s investment theme may face intense competition and potentially rapid product obsolescence. There can be no assurance these companies will be able to successfully protect their intellectual property to prevent the misappropriation of their technology, or that competitors will not develop technology that is substantially similar or superior to such	

companies' technology. As a result, the stock price of companies within a Fund's investment theme may vary widely and abruptly decline in value.																		
FEES AND CHARGES																		
WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT? Investors should note that subscriptions for Shares through any distributor appointed by the Management Company may incur additional fees and charges. Payable directly by you (as a percentage of your gross investment sum) <table><tr><th>Share classes</th><th>Initial Sales Charge / Entry Charge</th><th>Contingent Deferred Sales Charge²</th><th>Exchange Charge / Switching Fee</th></tr><tr><td>A</td><td>Currently 5.00% [max. 5.75%]</td><td>Currently 0.00% [max 1.00%]</td><td>Currently 1.00% [max 1.00%]</td></tr></table> Payable by the Fund from invested proceeds to the Management Company, the Depositary and other parties <table><tr><th>Share classes</th><th>Annual Management Charge</th><th>Others</th></tr><tr><td>A</td><td>1.50%</td><td> - Annual Depositary Fee³: 0.01% to 0.14% p.a., or higher if the Fund's investment objective and policy provides for investments in equity securities of issuers in developing countries - Annual Admin Fee³: Max 0.20% p.a. and an additional amount (consisting of a fixed and variable component) per Investor Holding over one year period - Audit Fees (as of 30 June 2025): 0.28% - Miscellaneous Expenses (as of 30 June 2025): 0.66% - Annual Management Charge retained by management company: 52.5% to 100% - Annual Management Charge paid by management company to financial advisor or distributor (trailer fee)[*]: 0% to 47.5% </td></tr></table>				Share classes	Initial Sales Charge / Entry Charge	Contingent Deferred Sales Charge ²	Exchange Charge / Switching Fee	A	Currently 5.00% [max. 5.75%]	Currently 0.00% [max 1.00%]	Currently 1.00% [max 1.00%]	Share classes	Annual Management Charge	Others	A	1.50%	- Annual Depositary Fee³: 0.01% to 0.14% p.a., or higher if the Fund's investment objective and policy provides for investments in equity securities of issuers in developing countries - Annual Admin Fee³: Max 0.20% p.a. and an additional amount (consisting of a fixed and variable component) per Investor Holding over one year period - Audit Fees (as of 30 June 2025): 0.28% - Miscellaneous Expenses (as of 30 June 2025): 0.66% - Annual Management Charge retained by management company: 52.5% to 100% - Annual Management Charge paid by management company to financial advisor or distributor (trailer fee)[*]: 0% to 47.5%	Refer to the “Fees and Charges” section of the Singapore Prospectus and Appendix E – “Franklin Templeton Investment Funds Charges, Fees and Expenses” of the Luxembourg Prospectus.
Share classes	Initial Sales Charge / Entry Charge	Contingent Deferred Sales Charge ²	Exchange Charge / Switching Fee															
A	Currently 5.00% [max. 5.75%]	Currently 0.00% [max 1.00%]	Currently 1.00% [max 1.00%]															
Share classes	Annual Management Charge	Others																
A	1.50%	- Annual Depositary Fee³: 0.01% to 0.14% p.a., or higher if the Fund's investment objective and policy provides for investments in equity securities of issuers in developing countries - Annual Admin Fee³: Max 0.20% p.a. and an additional amount (consisting of a fixed and variable component) per Investor Holding over one year period - Audit Fees (as of 30 June 2025): 0.28% - Miscellaneous Expenses (as of 30 June 2025): 0.66% - Annual Management Charge retained by management company: 52.5% to 100% - Annual Management Charge paid by management company to financial advisor or distributor (trailer fee)[*]: 0% to 47.5%																
VALUATIONS AND EXITING FROM THIS INVESTMENT																		
HOW OFTEN ARE VALUATIONS AVAILABLE? - Daily valuations are available on Dealing Days. - The indicative NAV and actual NAV per share of each Fund and Share Class may be obtained from the Singapore representative and will be published on the Singapore representative's website (www.franklintempleton.com.sg) one Singapore Business Day after the relevant Dealing Day. HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO? - To exit the Fund you should complete the relevant sale form, together with such other documents as may be required and submit it to the Singapore representative or through the financial advisor or distributor from whom you purchased the Fund, the Internet or any other sales channels, if applicable. Please ensure that all relevant documents have been submitted. - Some appointed distributors may offer a cancellation policy whereby you will not incur the sales charges if you sell during the relevant period (the Fund does not offer such cancellation policy). You will however take the risk of a decline in the Fund's NAV since you purchased it and certain administrative fees may apply. - Sale proceeds will be paid within three Dealing Days following the Dealing Day of the receipt and acceptance of the sale request. Sale proceeds from				Refer to the “Purchase of Shares”, “Sale of Shares” and “Obtaining Price Information” sections of the Singapore Prospectus.														

investments using SRS monies (if applicable) will be returned to your SRS account. - Your exit price is determined as follows: - If the Singapore representative receives and accepts the sale request on or before 4 p.m. on a Dealing Day, you will be paid a price based on the net asset value of the Shares applicable on that day. - If the Singapore representative receives and accepts the sale request after 4 p.m. on a Dealing Day, you will be paid a price based on the net asset value of the Shares at the close of the next Dealing Day. - The sales proceeds that you will receive will be the exit price multiplied by the number of shares sold, less any charges. The following illustrates the sales proceeds on a sale of 1,000 Class A SGD share class shares at an exit price of S\$12.50 and assuming no Contingent Deferred Sales Charge: <table> <tr> <td>Exit price x Number of shares sold</td> <td>= Gross Sales Proceeds</td> </tr> <tr> <td>S\$12.50 x 1,000</td> <td>= S\$12,500</td> </tr> <tr> <td>Gross Sales Proceeds – Exit Charges</td> <td>= Net Sales Proceeds</td> </tr> <tr> <td>S\$12,500-S\$0.00</td> <td>= S\$12,500</td> </tr> </table>	Exit price x Number of shares sold	= Gross Sales Proceeds	S\$12.50 x 1,000	= S\$12,500	Gross Sales Proceeds – Exit Charges	= Net Sales Proceeds	S\$12,500-S\$0.00	= S\$12,500	
Exit price x Number of shares sold	= Gross Sales Proceeds								
S\$12.50 x 1,000	= S\$12,500								
Gross Sales Proceeds – Exit Charges	= Net Sales Proceeds								
S\$12,500-S\$0.00	= S\$12,500								
CONTACT INFORMATION									
HOW DO YOU CONTACT US? - For account-related matters and product information, kindly contact the financial advisor or distributor from whom you purchased the Fund. - For product-related queries, kindly contact Templeton Asset Management Ltd at 7 Temasek Boulevard, #26-03 Suntec Tower One, Singapore 038987, tel: +65 6241 2662, website: www.franklintempleton.com.sg. Our Client Dealer Services Representative is available at tel: +65 6337 3933, email: cdsspr@franklintempleton.com.									
GLOSSARY									
Dealing Day : means each day which is both a Valuation Day and a Singapore Business Day, or otherwise as the Directors may from time to time determine. NAV : means Net Asset Value. Singapore Business Day : means a day (except Saturdays, Sundays and public holidays) on which commercial banks are open for business in Singapore. UCITS : means an undertaking for collective investment in transferable securities. Valuation Day : means a day on which the New York Stock Exchange is open for normal business (other than during a suspension of normal dealing). Further information on the applicable Valuation Days for the Fund can be found on the website: http://www.franklintempleton.lu.									

¹ The Prospectus is available for collection from Templeton Asset Management Ltd at 7 Temasek Boulevard, #26-03 Suntec Tower One, Singapore 038987 and its appointed distributors during business hours, or accessible at www.franklintempleton.com.sg.

² Based on the lesser of the value of Shares being sold (exclusive of reinvested dividends) or the total cost of Shares when purchased.

³ Payable to custodian, registrar and transfer, corporate, domiciliary and administrative agent (as applicable).

* Your financial adviser or distributor is required to disclose to you the amount of trailer fee it receives from the management company.